Recognized health and medicare policy expert John Rother and participatory medicine pioneer Dr. Danny Sands to help guide clinical-grade biometric device manufacturer leadership team
REDWOOD CITY, CA – May 10, 2016 – Biotricity Inc. (OTCQB: BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has established its board of advisors comprised of policy leader and former AARP executive John Rother and healthcare informatics professional Dr. Danny Sands. This team of experts will provide non-binding strategic advice to Biotricity as it continues to develop its next generation wearable devices.
“Wearable technology is rapidly increasing in popularity, and developers are continuing to find new and innovative ways to put it to good use,” said John Rother, President and CEO of the National Coalition on Health Care and Biotricity Advisor. “Biotricity’s innovative solutions have the potential to ease the growing financial burden chronic diseases have on the healthcare system. I look forward to providing guidance and to helping the company achieve their goal of revolutionizing how healthcare practitioners and individuals manage their health and wellness goals.”
Dr. Danny Sands, a consultant, thought leader, and primary care physician, commented, “Biotricity’s R&D focuses on the preventive healthcare market with a vision of putting health management into the hands of the individual, empowering the self-management of both critical and chronic conditions. As a medical technology company, Biotricity is committed to improving healthcare by developing medical-grade solutions that aid chronic disease prevention and management. The company and its executives are an impressive team, and I look forward to helping them establish clear policy positions and advocacy strategies as they develop and bring their medically relevant devices to market.” Biotricity’s new board of advisors will provide the company with timely insight and expert advice from industry authorities who have a deep understanding of medical device technology and the policies needed to bring innovative products to market.
Advisory board members include:
John Rother, JD – Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation.
Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”
Daniel Sands, MD, MPH – Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement.
He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.
“Our advisory board members are uniquely qualified to help direct us, as we continue to develop innovative, next generation wearables,” said Waqaas Al-Siddiq, founder, president and CEO of Biotricity. “Dr. Sands will be instrumental in ensuring we continue to develop solutions that are optimized for individuals yet are capable of transmitting clinical-grade, scientifically accurate and reliable data. As one of the world’s most respected and admired health and social security policy pioneers, I am thrilled to welcome John to the board and look forward to tapping into his public policy research and analysis, public education, and health advocacy experience.”
TWEET THIS: #policy visionary John Rother and #participatorymedicine expert @DrDannySands joins @Biotricity_inc board of advisors #wearables
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com or follow on Twitter: @biotricity_inc Facebook facebook.com/biotricity/ or LinkedIn linkedin.com/company/biotricity-measuring-vitals.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin
Chris@mccoinsmith.com
508-429-5988
Richard Smith
rick@mccoinsmith.com
978-433-3304
Investor Relations:
Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348
